Intellia Therapeutics, Inc. (NTLA) Stock Overview
NASDAQ · Healthcare · Biotechnology
✓ Sourced directly from Yahoo Finance · Checked for accuracy at every rebuild · Snapshot: 6 September 2026
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9)…
Source: Yahoo Finance
Sector & Industry
Intellia Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry group. It is listed on the NASDAQ exchange.
Intellia Therapeutics, Inc. at a Glance
| Company | Intellia Therapeutics, Inc. |
| Ticker | NTLA |
| Exchange | NASDAQ |
| Currency | USD |
| Price | $12.74 |
| Market cap | $1.79B |
| P/E ratio (trailing) | — |
| EPS (trailing) | -$3.34 |
| 52-week high | $28.25 |
| 52-week low | $7.95 |
| Dividend yield | — |
| Ex-dividend date | — |
| Beta | 1.82 |
| Return on equity (ROE) | -55.44% |
| Debt-to-equity | 10.09% |
| Average volume | 4.60M |
| Shares outstanding | 140.13M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 377 |
| Country | United States |
Investing Essentials
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Evaluating pharma pipelines, devices and healthcare economics.
Check Price →Peter Lynch on how everyday investors can spot winners before the professionals do.
Check Price →Benjamin Graham's classic on value investing — the book Warren Buffett calls the best ever written on the subject.
Check Price →Frequently Asked Questions
- What is Intellia Therapeutics, Inc.'s current P/E ratio?
- Intellia Therapeutics, Inc. (NTLA) has a trailing P/E ratio of — as of our 6 September 2026 data snapshot. Learn what the P/E ratio means →
- What is Intellia Therapeutics, Inc.'s market capitalisation?
- Intellia Therapeutics, Inc.'s market cap is $1.79B based on our latest snapshot. See how it ranks by market cap →
- What is NTLA's 52-week range?
- Over the past 52 weeks, NTLA has traded between $7.95 and $28.25. What does the 52-week range mean? →
- How volatile is Intellia Therapeutics, Inc. compared to the market?
- Intellia Therapeutics, Inc. has a beta of 1.82, meaning it has historically moved more than the broader market. What does beta measure? →
- Does Intellia Therapeutics, Inc. pay a dividend?
- Intellia Therapeutics, Inc. does not currently pay a dividend according to our latest data.
- What exchange is NTLA listed on?
- NTLA is listed on the NASDAQ. Browse all NASDAQ-listed stocks →
- What sector is Intellia Therapeutics, Inc. in?
- Intellia Therapeutics, Inc. is classified in the Healthcare sector. Compare with Healthcare peers →
Prefer raw numbers at a glance? Browse our size and reference charts for quick lookups.
Many readers keep a stock investing journal to log positions and theses alongside pages like this one, and a dedicated financial calculator to hand for quick valuation maths.
Recommended Reading & Tools
Morgan Housel's short lessons on behaviour, luck and long-term wealth.
Check Price →Burton Malkiel's evidence-based guide to markets, indexing and long-term strategy.
Check Price →Philip Fisher on what makes a business worth owning for the long term.
Check Price →